UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

RWD87 Real-World Treatment Patterns, Healthcare Costs, and Healthcare Resource Utilization in Patients in the US With Metastatic Non-Small Cell Lung Cancer Receiving Systemic Anticancer Therapy

Value in health, 2024-06, Vol.27 (6), p.S374-S374

2024

Volltextzugriff (PDF)

PCN96 - Retrospective Study of Frequency and Cost of Multiple Myeloma (MM) Complications and Treatment Related Adverse Events (AES)

Value in health, 2016-11, Vol.19 (7), p.A725-A725

2016

Volltextzugriff (PDF)

PCN94 - Healthcare Costs Among Multiple Myeloma (MM) Patients (PTS) without Stem Cell Transplant (SCT)

Value in health, 2016-11, Vol.19 (7), p.A725-A725

2016

Volltextzugriff (PDF)

Retrospective Study of Frequency and Cost of Multiple Myeloma (MM) Complications and Treatment Related Adverse Events (AES)

Value in health, 2016-11, Vol.19 (7), p.A725-A725

2016

Volltextzugriff (PDF)

Healthcare Costs Among Multiple Myeloma (MM) Patients (PTS) without Stem Cell Transplant (SCT)

Value in health, 2016-11, Vol.19 (7), p.A725-A725

2016

Volltextzugriff (PDF)

Treatment of peripheral neuropathic pain: A simulation model

European journal of pain, 2006-04, Vol.10 (3), p.279-279

2006

Volltextzugriff (PDF)

Vost Effectiveness of Blinatumomab Vs Inotuzomab Ozogamicin (INOTUZUMAB) in Adult Patients with Relapsed or Refracory (R/R) Acute Lymphoblastic Leukemia (ALL) with Zero or One Prior Salvage Therapy (S0/S1) from a US Payer Perspective

Value in health, 2018-05, Vol.21, p.S253-S254

2018

Volltextzugriff (PDF)

PSY52 - Vost Effectiveness of Blinatumomab Vs Inotuzomab Ozogamicin (INOTUZUMAB) in Adult Patients with Relapsed or Refracory (R/R) Acute Lymphoblastic Leukemia (ALL) with Zero or One Prior Salvage Therapy (S0/S1) from a US Payer Perspective

Value in health, 2018-05, Vol.21, p.S253-S254

2018

Volltextzugriff (PDF)

PCN93 - Treatment Practice Patterns, Healthcare Resource Utilization (HRU), and Costs in Newly Diagnosed Patients with Therapy-Related Acute Myeloid Leukemia (TAML) or AML with Myelodysplasia-Related Changes (AML-MRC) in a United States (US) Commercially Insured Population

Value in health, 2018-05, Vol.21, p.S27-S27

2018

Volltextzugriff (PDF)

Treatment Practice Patterns, Healthcare Resource Utilization (HRU), and Costs in Newly Diagnosed Patients with Therapy-Related Acute Myeloid Leukemia (TAML) or AML with Myelodysplasia-Related Changes (AML-MRC) in a United States (US) Commercially Insured Population

Value in health, 2018-05, Vol.21, p.S27

2018

Volltextzugriff (PDF)

Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes a retrospective cohort study

Diabetes care, 2003-11, Vol.26 (11), p.2983-2989

2003

Volltextzugriff (PDF)

EORTC-8D UTILITY VALUES IN PATIENTS WITH PHILADELPHIA NEGATIVE (PH-) RELAPSED/REFRACTORY (R/R) B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-CELL ALL) RECEIVING BLINATUMOMAB VERSUS STANDARD OF CARE (SOC) CHEMOTHERAPY IN A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY (TOWER)

Value in health, 2017-05, Vol.20 (5), p.A123

2017

Volltextzugriff (PDF)

Cost-effectiveness of fluvastatin following successful first percutaneous coronary intervention

The Annals of pharmacotherapy, 2005-04, Vol.39 (4), p.610-616

2005

Volltextzugriff (PDF)

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer

Cancer management and research, 2021-01, Vol.13, p.8179-8189

2021

Volltextzugriff (PDF)

P1-12-24: Adherence and Persistence with Lapatinib in Women with Metastatic Breast Cancer Who Were Previously Treated with Trastuzumab

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.P1-P1-12-24

2011

Volltextzugriff (PDF)

PSY5 COST-EFFECTIVENESS OF DEFERASIROX VERSUS DEFEROXAMINE IN TRANSFUSION-DEPENDENT THALASSAEMIA PATIENTS IN HONG KONG—AN INITIAL ANALYSIS

Value in health, 2010, Vol.13 (7), p.A565-A565

2010

Volltextzugriff (PDF)

Earlier Use Of Fluticasone Propionate/Salmeterol Combination (FSC) After An Asthma Exacerbation Reduces Subsequent Exacerbations Of Asthma And Albuterol Use

Journal of allergy and clinical immunology, 2010-02, Vol.125 (2), p.AB171-AB171

2010

Volltextzugriff (PDF)

PCN105 PATIENT PREFERENCE-BASED UTILITY WEIGHTS FROM THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY-GENERAL (FACT-G) IN WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER RECEIVING LETROZOLE PLUS LAPATINIB OR LETROZOLE ALONE

Value in health, 2010, Vol.13 (3), p.A43-A44

2010

Volltextzugriff (PDF)

Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with early stage breast cancer based on results of the ABCSG-12 study

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (2_Supplement), p.2112

2009

Volltextzugriff (PDF)

Conclusions regarding relative cost–utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature

Annals of oncology, 2007-01, Vol.18 (1), p.197-198

2007

Volltextzugriff (PDF)

The Causal Role for Genital Ulcer Disease as a Risk Factor for Transmission of Human Immunodeficiency Virus: An Application of the Bradford Hill Criteria

Sexually transmitted diseases, 1996-09, Vol.23 (5), p.429-440

1996

Volltextzugriff (PDF)

PCN74 ADDING ZOLEDRONIC ACID TO ENDOCRINE THERAPY IN PREMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY BREAST CANCER CAN BE COST-EFFECTIVE FROM ITALIAN, SPANISH, AND PORTUGUESE HEALTH-CARE PERSPECTIVES, BASED ON THE ABCSG-12 TRIAL

Value in health, 2010, Vol.13 (7), p.A265-A265

2010

Volltextzugriff (PDF)

PMC2 ESTIMATING COST-EFFECTIVENESS BASED ON RESULTS OF UNCONTROLLED CLINICAL TRIALS: OFATUMUMAB FOR THE TREATMENT OF FLUDARABINE- AND ALEMTUZUMAB-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

Value in health, 2010, Vol.13 (7), p.A328-A329

2010

Volltextzugriff (PDF)

Cost effectiveness of carvedilol for heart failure

The American journal of cardiology, 1999-03, Vol.83 (6), p.890-896

1999

Volltextzugriff (PDF)

PCN73 COST-EFFECTIVENESS OF ADDING ZOLEDRONIC ACID TO ENDOCRINE THERAPY IN PREMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY BREAST CANCER IN GREECE, BASED ON THE ABCSG-12 STUDY

Value in health, 2009, Vol.12 (7), p.A270-A270

2009

Volltextzugriff (PDF)

1 – 25 von 170

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(145)

Publikationsform

Artikel
(90)
Bücher
(36)
Buchkapitel
(34)
Texte
(9)
Reviews
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(20)
Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Female
(16)
History
(16)
Humanities And Social Sciences
(16)
Male
(13)
Thema Editeur
(12)
Aged
(10)
Biological And Medical Sciences
(8)
Medical Sciences
(8)
Middle Aged
(8)
Internal Medicine
(7)
Adult
(5)
Biography, Literature And Literary Studies
(5)
Cost-Benefit Analysis
(5)
General & Internal Medicine
(5)
History And Archaeology
(5)
Literature
(5)
Medicine, General & Internal
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

RWD87 Real-World Treatment Patterns, Healthcare Costs, and Healthcare Resource Utilization in Patients in the US With Metastatic Non-Small Cell Lung Cancer Receiving Systemic Anticancer Therapy

PCN96 - Retrospective Study of Frequency and Cost of Multiple Myeloma (MM) Complications and Treatment Related Adverse Events (AES)

PCN94 - Healthcare Costs Among Multiple Myeloma (MM) Patients (PTS) without Stem Cell Transplant (SCT)

Retrospective Study of Frequency and Cost of Multiple Myeloma (MM) Complications and Treatment Related Adverse Events (AES)

Healthcare Costs Among Multiple Myeloma (MM) Patients (PTS) without Stem Cell Transplant (SCT)

Treatment of peripheral neuropathic pain: A simulation model

Vost Effectiveness of Blinatumomab Vs Inotuzomab Ozogamicin (INOTUZUMAB) in Adult Patients with Relapsed or Refracory (R/R) Acute Lymphoblastic Leukemia (ALL) with Zero or One Prior Salvage Therapy (S0/S1) from a US Payer Perspective

PSY52 - Vost Effectiveness of Blinatumomab Vs Inotuzomab Ozogamicin (INOTUZUMAB) in Adult Patients with Relapsed or Refracory (R/R) Acute Lymphoblastic Leukemia (ALL) with Zero or One Prior Salvage Therapy (S0/S1) from a US Payer Perspective

PCN93 - Treatment Practice Patterns, Healthcare Resource Utilization (HRU), and Costs in Newly Diagnosed Patients with Therapy-Related Acute Myeloid Leukemia (TAML) or AML with Myelodysplasia-Related Changes (AML-MRC) in a United States (US) Commercially Insured Population

Treatment Practice Patterns, Healthcare Resource Utilization (HRU), and Costs in Newly Diagnosed Patients with Therapy-Related Acute Myeloid Leukemia (TAML) or AML with Myelodysplasia-Related Changes (AML-MRC) in a United States (US) Commercially Insured Population

Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes a retrospective cohort study

EORTC-8D UTILITY VALUES IN PATIENTS WITH PHILADELPHIA NEGATIVE (PH-) RELAPSED/REFRACTORY (R/R) B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-CELL ALL) RECEIVING BLINATUMOMAB VERSUS STANDARD OF CARE (SOC) CHEMOTHERAPY IN A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY (TOWER)

Cost-effectiveness of fluvastatin following successful first percutaneous coronary intervention

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer

P1-12-24: Adherence and Persistence with Lapatinib in Women with Metastatic Breast Cancer Who Were Previously Treated with Trastuzumab

PSY5 COST-EFFECTIVENESS OF DEFERASIROX VERSUS DEFEROXAMINE IN TRANSFUSION-DEPENDENT THALASSAEMIA PATIENTS IN HONG KONG—AN INITIAL ANALYSIS

Earlier Use Of Fluticasone Propionate/Salmeterol Combination (FSC) After An Asthma Exacerbation Reduces Subsequent Exacerbations Of Asthma And Albuterol Use

PCN105 PATIENT PREFERENCE-BASED UTILITY WEIGHTS FROM THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY-GENERAL (FACT-G) IN WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER RECEIVING LETROZOLE PLUS LAPATINIB OR LETROZOLE ALONE

Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with early stage breast cancer based on results of the ABCSG-12 study

Conclusions regarding relative cost–utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature

The Causal Role for Genital Ulcer Disease as a Risk Factor for Transmission of Human Immunodeficiency Virus: An Application of the Bradford Hill Criteria

PCN74 ADDING ZOLEDRONIC ACID TO ENDOCRINE THERAPY IN PREMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY BREAST CANCER CAN BE COST-EFFECTIVE FROM ITALIAN, SPANISH, AND PORTUGUESE HEALTH-CARE PERSPECTIVES, BASED ON THE ABCSG-12 TRIAL

PMC2 ESTIMATING COST-EFFECTIVENESS BASED ON RESULTS OF UNCONTROLLED CLINICAL TRIALS: OFATUMUMAB FOR THE TREATMENT OF FLUDARABINE- AND ALEMTUZUMAB-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

Cost effectiveness of carvedilol for heart failure

PCN73 COST-EFFECTIVENESS OF ADDING ZOLEDRONIC ACID TO ENDOCRINE THERAPY IN PREMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY BREAST CANCER IN GREECE, BASED ON THE ABCSG-12 STUDY

Suchergebnisse filtern